Acura Pharmaceuticals amends loan schedule with Abuse Deterrent Pharma, raising total principal to $10.89 million

• Acura Pharmaceuticals amended the loan schedule to its Secured Promissory Note with Abuse Deterrent Pharma.
• Aggregate principal rose to $10.89 million from $9.39 million under the original $2.32 million note.
• The schedule adds $7.08 million of loans dated Dec. 22, 2022 through Dec. 31, 2025.
• It also adds $1.5 million of new advances dated Jan. 2, 2026 through July 17, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-086651), on July 24, 2026, and is solely responsible for the information contained therein.